[Drug therapy in hypertension 1977. Empirical and rational viewpoints].
D018663:Adrenergic Agents / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000367:Age Factors; D000368:Aged; D001810:Blood Volume / Q000187:drug effects; D004232:Diuretics / Q000627:therapeutic use; D004358:Drug Therapy / Q000191:economics; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control; D010349:Patient Compliance; D011188:Potassium / Q000097:blood; D011433:Propranolol / Q000627:therapeutic use; D012306:Risk; D012737:Sex Factors; D013557:Switzerland; D013565:Sympatholytics / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood; D014665:Vasodilator Agents / Q000627:therapeutic use
D018663:Adrenergic Agents; D000319:Adrenergic beta-Antagonists; D004232:Diuretics; D013565:Sympatholytics; D014280:Triglycerides; D014665:Vasodilator Agents; D014527:Uric Acid; D011433:Propranolol; D011188:Potassium
Medikamentöse Hypertoniebehandlung 1977. Empirische und rationale Gesichtspunkte.